IPO Journey
Nuwellis, Inc.
IPO Date: June 8, 2026 · 7 filings tracked
Final Offer Terms
Ticker
NUWE
Exchange
Nasdaq
Offer Price
$0.30
Shares Offered
1,903,338
Estimated Proceeds
$571.0K
Underwriters
Led by Ladenburg Thalmann & Co. Inc.
Filing Timeline
1
S-1
May 30, 2025
- Innovative Aquadex SmartFlow system provides specialized ultrafiltration for heart failure and kidney patients.
- Targeting a $4.2 million capital raise to bolster operations and growth initiatives.
2
S-1/A
June 3, 2025
- Specialized medical device focus on fluid management for heart and kidney failure patients.
- Recurring revenue model driven by high-margin, single-use blood sets and catheters.
3
424B4
Material Update
June 10, 2025
- Innovative 'razor and blade' business model centered on the Aquadex ultrafiltration system.
- Addresses a critical medical need for patients with severe heart or kidney-related fluid overload.
Changes from previous filing
- ▸ Exchange: Nasdaq
- ▸ Final offer price: $0.3 per share
- ▸ Shares offered: 406,755
- ▸ Estimated proceeds: $0M
- ▸ Underwriters: Ladenburg Thalmann
4
S-1
May 22, 2026
- Proprietary Aquadex SmartFlow system addresses critical fluid overload in heart and kidney patients.
- Recurring revenue model driven by single-use disposable kits for every treatment session.
Changes from previous filing
- ▸ Exchange: Nasdaq Capital Market
- ▸ Final offer price: $1.03 per share
- ▸ Shares offered: 4,854,369
- ▸ Estimated proceeds: $5M
- ▸ Underwriters: Ladenburg Thalmann & Co. Inc.
5
S-1/A
May 29, 2026
- FDA-cleared Aquadex SmartFlow system provides a precise alternative to unpredictable diuretics for fluid overload.
- Recurring revenue model driven by single-use blood sets and catheters used in every treatment.
Changes from previous filing
- ▸ Final offer price: $0.76 per share
- ▸ Shares offered: 6,578,948
6
S-1/A
June 4, 2026
- Proprietary Aquadex SmartFlow system provides a specialized 'kidney outside the body' solution for fluid overload.
- Addresses a critical medical need for patients with heart or kidney failure where standard medication fails.
424B4
Final Pricing
June 8, 2026
- Proprietary Aquadex technology provides a precise, high-tech alternative to traditional diuretics for fluid management.
- Recurring revenue model driven by the sale of single-use sterile blood circuits for every procedure.
Changes from previous filing
- ▸ Exchange: Nasdaq
- ▸ Final offer price: $0.3 per share
- ▸ Shares offered: 1,903,338
- ▸ Estimated proceeds: $0M
Disclaimer: AI-generated analysis for informational purposes only. Not financial advice. Always conduct your own research.